Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $2.54 on Tuesday. The business has a 50-day moving average price of $3.05 and a 200 day moving average price of $4.45. Kyverna Therapeutics has a 1-year low of $2.38 and a 1-year high of $29.96.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $18.40.

Institutional Trading of Kyverna Therapeutics

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE raised its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,788 shares of the company’s stock after buying an additional 6,400 shares during the quarter. Bank of America Corp DE owned about 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.